title: Influence of prostaglandin E1 infusion on hemostasis in orthotopic liver transplantation.
abstract: In the control group, a significant decrease in platelet aggregability could be demonstrated after reperfusion. This was paralleled by a decrease in platelet counts. When PGE1 was infused during OLT, the post-reperfusional decreases in platelet aggregability and platelet counts in the control group could be prevented. Furthermore, our investigation demonstrated that PGE1 infusion led to higher t-PA activity during the anhepatic phase. This was paralleled and followed by lower alpha 2AP levels at the end of the anhepatic phase and after reperfusion. The higher t-PA levels in the PG group did not result in clinical signs of hyperfibrinolysis during OLT. The aprotinin administration in both groups is most certainly responsible for the absence of hyperfibrinolytic signs in the TEG and the low overall requirement for transfusions, explaining the comparable transfusion rate in the two groups (Fig. 5). Further investigations involving more patients are required to evaluate the clinical effect of PGE1 therapy.
authors.affiliation: Department of Internal Medicine, University Clinic Rudolf Virchow, Berlin, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Himmelreich
authors.forename: K
authors.initials: K
authors.lastname: Hundt
authors.forename: W O
authors.initials: WO
authors.lastname: Bechstein
authors.forename: R
authors.initials: R
authors.lastname: Rossaint
authors.forename: P
authors.initials: P
authors.lastname: Neuhaus
authors.forename: H
authors.initials: H
authors.lastname: Riess
mesh_terms: D000527:Alprostadil / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007611:Aprotinin / Q000008:administration & dosage / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D016913:Blood Component Transfusion; D001798:Blood Proteins / Q000032:analysis; D003131:Combined Modality Therapy; D006487:Hemostasis / Q000187:drug effects*; D006488:Hemostasis, Surgical / Q000379:methods; D006801:Humans; D007262:Infusions, Intravenous; D007432:Intraoperative Period; D016031:Liver Transplantation / Q000009:adverse effects / Q000502:physiology*; D010974:Platelet Aggregation / Q000187:drug effects
chemical_list: D015415:Biomarkers; D001798:Blood Proteins; D007611:Aprotinin; D000527:Alprostadil